Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Clinical results of Mitraclip in degenerative mitral valve regurgitation”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Role of embolic protection during Transcatheter Aortic valve replacement”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Eduardo de Marchena, entitled “New horizons in percutaneous mitral valve implantation”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Agustín Vecchia. Paravalvular leak was once considered the greatest disadvantage of TAVR when compared to conventional surgery. Nowadays, new devices and more-experienced operators have managed to “control” this phenomenon, keeping related statistics within acceptable ranges. Repositionable-valve Lotus may probably offer the most effective solution for this event; however, it is associated with high rates of<a href="https://solaci.org/en/2017/07/19/lotus-valve-performance-related-to-pacemaker-implantation-in-patients-after-tavr/" title="Read more" >...</a>
As experience increases, transcatheter aortic valve replacement (TAVR) has expanded to different populations and anatomies. This study sought to compare technical and clinical outcomes in patients with bicuspid versus tricuspid aortic stenosis from the Bicuspid AS TAVR Multicenter Registry. Outcomes of 561 patients with bicuspid valves and 4546 patients with tricuspid valves were compared. Propensity score matching was used<a href="https://solaci.org/en/2017/07/05/transcatheter-valve-replacement-in-the-bicuspid-valve-is-increasingly-performed-but-challenges-remain/" title="Read more" >...</a>
Certain studies have carried out a tomographic follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and described the frequency of leaflet thrombosis; however, in most cases, it is unclear whether this finding requires some sort of intervention. The difference between this work and those previously published is that this study is not focused on imaging, it<a href="https://solaci.org/en/2017/06/28/incidence-characteristics-and-treatment-of-valve-thrombosis-after-tavr/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Surgical aortic valve replacement (SAVR) continues to be elective, but the presence of post-procedural acute myocardial infarction (AMI) has been associated to bad evolution. Despite the proven benefits of TAVR for high risk patients and the progress shown by patients of intermediate risk, the incidence of post implantation MI has<a href="https://solaci.org/en/2017/06/13/tavr-presents-less-post-procedural-mi-than-surgical-aortic-valve-replacement/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The balloon aortic valvuloplasty (BAV) was introduced by Dr. Cribier in 1986. However, given its poor results, soon after it fell into disuse. With the introduction of TAVR, it saw a revival as bridge for another intervention, even though it is still resisted in many places. The present study<a href="https://solaci.org/en/2017/06/07/in-hospital-morbid-mortality-rates-for-balloon-aortic-valvuloplasty-are-similar-to-those-for-transcatheter-aortic-valve-implantation/" title="Read more" >...</a>
Courtesy of the SBHCI. Bioprosthetic surgically-implanted valves degenerate over time, while patients become too old and are at high risk for reoperation. Transcatheter aortic valve implantation inside a deteriorated surgically-implanted valve (a valve-in-valve procedure) is an emerging alternative. The VIVA trial was designed to offer systematic and prospective data from patients treated with<a href="https://solaci.org/en/2017/05/30/viva-post-market-study-more-evidence-for-the-valve-in-valve-technique/" title="Read more" >...</a>
Courtesy of the SBHCI. The risk of surgical mitral valve replacement in patients with significant annular calcification is very high. There are isolated reports of transcatheter mitral valve replacement with balloon-expandable valve in this patient population. In consequence, this multicenter registry tries to concentrate information and analyzes the outcomes a year after the procedure. <a href="https://solaci.org/en/2017/05/30/mitral-valve-global-registry-transcatheter-mitral-valve-replacement-due-to-native-valve-disease/" title="Read more" >...</a>